Bristol Myers Squibb (CGT Mfg) vs Novartis: CDMO Comparison
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and Novartis on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Novartis has more FDA inspections on record (14 vs 5) — a deeper regulatory paper trail.
- Bristol Myers Squibb (CGT Mfg) carries a cleaner inspection mix — no OAI classifications versus 2 for Novartis.
- Novartis has materially broader EMA GMP coverage (47 active certificates vs 1) — stronger EU footprint.
- Novartis has stronger MHRA / UK coverage (3 compliant certificates vs 1).
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (577 vs 136) — a broader sponsor book.
On a 13-modality CDMO landscape, both Bristol Myers Squibb (CGT Mfg) and Novartis qualify as CAR-T manufacturers; Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score for CAR-T programs in this comparison.
What to evaluate for CAR-T programs
Both Bristol Myers Squibb (CGT Mfg) and Novartis qualify as CAR-T CDMOs. When choosing between them for CAR-T programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Vector supply
CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost.
Autologous logistics & turnaround
Autologous CAR-T lives or dies on vein-to-vein time and chain-of-identity. Evaluate scheduling, apheresis handling, and cryo-logistics.
Closed, scalable processing
Closed and automated platforms reduce contamination risk and support parallel patient slots. Ask about cleanroom grade and concurrent-batch capacity.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs Novartis
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or Novartis?
Bristol Myers Squibb (CGT Mfg) has 5 FDA inspections on record (NAI 2 / VAI 3 / OAI 0) and 0 warning letters. Novartis has 14 FDA inspections on record (NAI 6 / VAI 6 / OAI 2) and 0 warning letters.
How do Bristol Myers Squibb (CGT Mfg) and Novartis compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. Novartis holds 47 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or Novartis?
Bristol Myers Squibb (CGT Mfg) is matched to 577 ClinicalTrials.gov records as a manufacturing partner; Novartis is matched to 136. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for CAR-T manufacturing — Bristol Myers Squibb (CGT Mfg) or Novartis?
Both Bristol Myers Squibb (CGT Mfg) and Novartis are tagged as CAR-T CDMOs in our directory, so both are credible options for CAR-T programs. The most important differentiator for CAR-T selection is typically vector supply: CAR-T needs a lentiviral or retroviral vector. Confirm whether the CDMO produces vector in-house or coordinates a supplier, and how that affects timelines and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 91/100 and Novartis carries 88/100 — essentially tied for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →